Despite the current therapeutic options, filamentous fungal infections are associated with high mortality rate especially in immunocompromised patients. In order to find a new potential therapeutic approach, the in vitro inhibitory effect of two antiarrhythmic agents, diltiazem and verapamil hydrochloride were tested against different clinical isolates of ascomycetous and mucoralean filamentous fungi. The in vitro combinations of these non-antifungal drugs with azole and polyene antifungal agents were also examined. Susceptibility tests were carried out using the broth microdilution method according to the instructions of the Clinical and Laboratory Standards Institute document M38-A2. Checkerboard microdilution assay was used to assess the interactions between antifungal and non-antifungal drugs. Compared to antifungal agents, diltiazem and verapamil hydrochloride exerted a relatively low antifungal activity with high minimal inhibitory concentration values (853-2731 μg/ml). Although in combination they could increase the antifungal activity of amphotericin B, itraconazole and voriconazole. Indifferent and synergistic interactions were registered in 33 and 17 cases, respectively. Antagonistic interactions were not revealed between the investigated compounds. However, the observed high MICs suggest that these agents could not be considered as alternative systemic antifungal agents.
INTRODUCTION
Filamentous fungi could be responsible for severe, opportunistic, life-threatening infections, especially among immunocompromised organ transplant and cancer patients [18] . Although the genus Aspergillus still remains the most common cause of invasive mould infections, non-Aspergillus moulds, such as Fusarium and Scedosporium species and members of the order Mucorales are also reported as emerging human pathogens in recent years [6, 19, 26] . Conventional antifungal drugs Acta Biologica Hungarica 68, 2017 Table 1 Literature overview of the antifungal properties of diltiazem and verapamil hydrochloride 
Ischemic heart diseases
Aspergillus spp., Candida spp. MIC range: 10-50 mg/ml [12, 13] Aspergillus fumigatus Inactive in the tested range: MIC > 640 µg/ml.
No interaction with ITC [2]
Candida albicans Increased the sensitivity to FLC.
MICs decreased from 5.5 to 0.83 µg/ml [4] Candida albicans Increased the antifungal activity of ketoconazole in vitro, found synergistic effect between them [14] Candida spp. Efficiently reversed the resistance to FLC [23] Aspergillus parasiticus Inhibited the aflatoxin production (> 490 µg/ml).
Growth inhibition was not observed [24] Candida albicans Inhibited the biofilm formation both alone and in combination with FLC [27] Candida albicans Inhibited the hyphal development (≥ 10 µg/ml), adhesion and gastrointestinal colonization [28] Candida albicans Inhibited the oxidative stress response MICs decreased from 5.5 to 0.83 µg/ml [4, 21, 25] Aspergillus parasiticus Inhibited the aflatoxin production (> 450 µg/ml).
Growth inhibition was not observed [24] VHC -verapamil hydrochloride; MIC -minimal inhibitory concentration; ITC -itraconazole; FLC -fluconazole; DHC -diltiazem hydrochloride.
applied in clinical practice often have limited activity against these pathogens [7] . Moreover, their long-term use may cause severe adverse effects in the patients. According to the recent studies, more than 1.6 million people die of a serious fungal infection each year despite the currently available antifungal treatments [9] . These facts underline the importance of developing novel, safely applicable antifungal therapeutic strategies. Based on previous studies, several non-antifungal medications possess secondary antifungal activity in vitro. Calcium channel blockers (CCBs), which are commonly used as antiarrhythmic drugs, block the Ca 2+ influx influencing the calmodulin system of the cell, which modulates metabolism and growth [1] . Verapamil hydrochloride (VHC) is a phenylalkylamine CCB, exerts inhibitory effect on Candida and Aspergillus species (Table 1) [2, 28, 29] . Diltiazem hydrochloride (DHC) belongs to the benzothiazepine class of CCBs and it is able to increase the sensitivity of Candida albicans to fluconazole (FLC) ( Table 1 ) [4] . These non-antifungal drugs, as monotherapeutic agents or in combination with conventional antifungals could serve as a potential basis for a novel therapeutic approach.
Considering the above-mentioned arguments, the objectives of the present work were (i) to examine and compare the in vitro antifungal effect of two CCBs (i.e., DHC and VHC) and conventional antifungal drugs (i.e., amphotericin B, AmB; FLC; itraconzole, ITC; ketoconazole, KTC; terbinafine, TRB; and voriconazole, VRC), and (ii) to investigate their in vitro combinations against clinical isolates of ascomycetous and mucoralean fungi.
MATERIALS AND METHODS

Strains
Ten ascomycetous and mucoralean fungal strains from different human infections were involved in the present study: Aspergillus fumigatus (Szeged Microbiology Collection, Szeged, Hungary; SZMC 2394 from keratitis), a member of the Fusarium solani species complex (SZMC 11412 from keratitis), Scedosporium aurantiacum (Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands; CBS 136046 from lung infection), Scedosporium boydii (CBS 120157 from lung infection), Trichoderma longibrachiatum (Devonian Botanic Garden, University of Alberta Herbarium and Microfungus Collection, Edmonton, Alberta, Canada; UAMH 7955 from sinus infection), Lichtheimia corymbifera (SZMC 95033 from lung infection), Rhizopus microsporus var. rhizopodiformis (CBS 102277 from rhinocerebral infection), Rhizomucor miehei (CBS 360.92 from kidney and liver infection), Rhizopus oryzae (CBS 146.90 from soft palate infection), and Rhizomucor pusillus (Swiss Federal Institute of Technology Culture Collection, Zurich, Switzerland; ETH M4920 from tracheal discharge). All the isolates were maintained on malt extract agar (MEA, Biolab) slants.
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Susceptibility testing
The in vitro minimal inhibitory concentration (MIC) values were determined using the broth microdilution method following the guidelines described in the CLSI M38-A2 document [5] .
The ] ) was investigated and compared. Stock solutions of non-antifungal agents were prepared in sterile distilled water, while antifungal agents were dissolved in the solvents recommended by CLSI M38-A2 document [5] . Further dilutions were prepared in the testing medium, RPMI-1640 buffered to pH 7.0 with 0.165 mol/l 3-[N-morpholino] propanesulfonic acid (Sigma-Aldrich). The final concentration ranges were 128-4096 µg/ml for CCBs and 0.25-128 µg/ml for antifungal drugs. Considering the speeds of germination and growth, microtiter plates of mucoralean fungi were evaluated after 24 hours, whilst Aspergillus, Fusarium and Trichoderma strains after 48 hours, and Scedosporium strains after 72 hours of incubation at 37 °C. Results were read using a microplate reader in well-scanning mode (SPECTROstar Nano, Germany). Untreated control samples served as growth controls and we take their absorbance (OD 620 ) as 100%. MIC was defined as the lowest concentration of the tested compound that totally inhibited the growth of the fungus on the basis of the OD 620 values as compared to the untreated control.
Combination tests
Interactions were investigated between CCBs and AmB, ITC, and VRC using the checkerboard microdilution method [8] . Interactions between VHC and AmB were not tested, since according to the drug information leaflet provided by the manufacturer, the co-administration of these two drugs should be avoided. The final concentration ranges of each drug were chosen based on the MIC data obtained by the antifungal susceptibility tests. Fractional inhibitory concentration index (FICI) values were calculated to describe the interactions between the compounds as described previously [11] . Synergism was defined as FICI ≤ 0.5, indifference as 0.5 < FICI ≤ 4, and antagonism was defined when FICI was > 4 [22] .
RESULTS
Susceptibility testing
Results of the susceptibility tests are presented in Table 2 . In general, the MICs of DHC and VHC were quite high, but mucoralean isolates (MIC range: 853-2048 µg/ ml) proved to be slightly more susceptible to these non-antifungal drugs than the Acta Biologica Hungarica 68, 2017 Table 2 In vitro antifungal susceptibility of the investigated filamentous fungal isolates 
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ascomycetous isolates (MIC range: 1024-2731 µg/ml). Differences in the susceptibility to antifungal drugs were also observed between the two groups: while VRC was more effective against ascomycetous fungi, mucoralean fungi proved to be more susceptible to AmB, ITC and KTC. Against the investigated Ascomycetes, KTC proved to be the most effective antifungal drug (MIC range: 2-24 µg/ml), followed by VRC (MIC range: 16-53 µg/ml). MICs of ITC were generally high, but A. fumigatus SZMC 2394 (MIC: 2 µg/ml) was susceptible to it. AmB and KTC proved to be the most effective antifungals against mucoralean isolates with MICs ranging between 0.04-1.33 µg/ml and 0.5-2 µg/ml, respectively. The growth of mucoralean fungi was also inhibited by low concentrations of CLT (MICs < 0.25 µg/ml) and TRB (MIC range: 0.3-4 µg/ml), except the case of R. oryzae CBS 146.90, where the MICs of 64 µg/ml for CLT and > 28 µg/ml for TRB were recorded. With one exception (S. aurantiacum CBS 136046, MIC: 64 µg/ml), FLC was ineffective against all isolates in the investigated concentration range. Summarizing, conventional antifungal drugs proved to be more effective than CCBs.
Combination tests
The results of the combination tests are summarized in Tables 3 and 4 . Compared to the single use, the relatively high MIC values (853-2731 µg/ml) of CCBs decreased or remained the same in the combination tests (MIC range: 32-> 2048 µg/ml). Antagonistic interactions were not detected between the investigated compounds. Synergistic and indifferent interactions were revealed in 17 and 33 cases, respectively. Between VHC and VRC, and DHC and VRC only indifferent interactions were observed; while the interactions of CCBs with ITC were synergistic in most cases. Between AmB and DHC no interactions were revealed against all mucoralean isolates, while against ascomycetous fungi synergistic and indifferent interactions were registered in three and two cases, respectively.
DISCUSSION
The antifungal effect of CCBs has been investigated previously against Candida and Aspergillus species, but data on its effect against other human pathogenic ascomycetous and mucoralean fungi are not reported in the literature (Table 1) . Basically, our results are in agreement with these reports: relative high concentrations of DHC and VHC inhibited the growth of the investigated fungal strains, MICs were between 853 and 2731 μg/ml (Table 2) . These values are much higher than their therapeutically available plasma levels (Table 1) . Khalaf et al. [12] observed a much broader and higher MIC range (10,000-50,000 μg/ml) for Aspergillus and Candida strains. Afeltra et al. [2] reported that VHC was inactive against Aspergillus fumigatus (MIC > 640 μg/ml). In another study, Aspergillus parasiticus also proved to be resistant to VHC and DHC, but their applied concentrations (<490 μg/ml and <450 μg/ml, respectively) could inhibit the aflatoxin production of this strain [24] . VHC inhibited the adhesion, gastrointestinal colonization and the oxidative stress response of C. albicans and significantly decreased the hyphal development in a concentration of ≥10 μg/ml [28, 29] . Our findings on the interactions between CCBs and conventional antifungal drugs are comparable to previously reported observations. We proved that DHC and VHC could interact synergistically with azoles and polyene antifungals (Tables 3, 4) . While in these tests the MICs of non-antifungal drugs were still beyond their in vivo achievable plasma concentrations, the MICs of AmB, ITC and VRC could be decreased to their therapeutic plasma levels [3, 10, 16] .
Krajewska-Kułak and Niczyporuk [14] reported that VHC and other CCBs increased the antifungal activity of ketoconazole against C. albicans strains in vitro and found synergistic effect between them. Afeltra et al. [2] observed no interaction between VHC and ITC against A. fumigatus. The sensitivity of C. albicans to FLC was increased dramatically in the presence of DHC and VHC [4] . Other calcium channel antagonists were tested by Liu et al. [17] against FLC-resistant Candida strains. All the CCBs exhibited no antifungal activity with MICs >512 μg/ml, although, in combination with FLC, strong synergistic interactions were revealed. Moreover, Pina-Vaz et al. [23] observed that FLC resistance of Candida strains could be efficiently reverted by the application of VHC.
As CCBs affect all eukaryotic cells, their potential clinical use as antifungal agents must be clarified by further studies. The influence of DHC and VHC on human peritoneal polymorphonuclear cells and monocytes were investigated by Levy et al. [15] . The authors reported that these CCBs significantly reduced the bactericidal and fungicidal activity of phagocytic cells in vitro, however in vivo this effect was not observed. In addition to this, CCBs are both substrates and inhibitors of the cytochrome P450 family CYP3A4. Their co-administration with other drugs that share the CYP3A4 pathway (e.g. azoles) may alter the pharmacokinetic properties and increase the plasma levels of both drugs [20] . Optimal therapeutic drug-level monitoring and dosage adjustments may also be necessary during therapy to avoid serious side effects.
In conclusion, the in vitro sensitivity of both ascomycetous and mucoralean fungi to azoles and AmB could be increased with the addition of DHC and VHC in the testing media. However, their observed high MIC values and low therapeutic plasma level suggest that these agents could not be administered systemically. A possible limitation of our study is that one isolate per species was investigated only, however antifungal susceptibility might vary among different isolates of the same species.
